DUBLIN – Michael Greve, one of Germany’s most successful internet entrepreneurs and investors, is personally committing €300 million (US$362 million) to building a portfolio of biotechnology firms focused on different aspects of aging. His investment vehicle, Kizoo Technology Capital GmbH, of Karlsruhe, has already provided seed funding to more than a dozen early stage firms. Greve is now ready to invest in follow-on rounds, particularly in four core companies he described as “category openers” in rejuvenation biotech. “We are really super focused, because there are so many things we could do,” he told BioWorld.